NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Common sense talk but I think you're being far too charitable from a governance standpoint. Betting the CEO has known about a trial redux for years. Likely right around the time she moved to the OTC. Powers believes she's covered herself with that FDA endpoint cautionary guidance blurb, and she probably has. It's really people here and a few authors like Lappin ignoring that Powers letter to the FDA and the 8k cautionary statement, so always have to remind myself of that.

On another note, I'm guessing when LL realized management was spending the cash on building out and selling manufacturing facilities instead of furthering trials, that's when their relationship allegedly soured.

So very curious with what the SEC was looking at the last years and why they moved on?? Was it Germany or something else? Would've loved to be a fly on the wall when the decision was made to assign Flaskworks to NWBO instead of Advent.